Free Trial

Janux Therapeutics (JANX) Projected to Post Earnings on Wednesday

Janux Therapeutics logo with Medical background

Key Points

  • Janux Therapeutics is set to report its Q2 2025 earnings on August 6, with analysts forecasting an EPS of (-$0.50) and revenue of $0.30 million for the quarter.
  • The company's stock is currently trading around $24.17 with a market cap of $1.43 billion, facing a 5.4% decline recently and a 52-week range between $22.48 and $71.71.
  • Raymond James has initiated coverage on Janux Therapeutics with an "outperform" rating and a target price of $65.00, while the average rating among analysts stands at "Buy" with a consensus price target of $91.89.
  • Five stocks to consider instead of Janux Therapeutics.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.50) per share and revenue of $0.30 million for the quarter.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Stock Down 1.9%

JANX stock traded down $0.45 during midday trading on Friday, reaching $23.56. 601,583 shares of the company's stock traded hands, compared to its average volume of 800,036. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -17.32 and a beta of 2.86. The firm's fifty day moving average price is $24.77 and its 200-day moving average price is $29.81. Janux Therapeutics has a 52 week low of $22.48 and a 52 week high of $71.71.

Wall Street Analyst Weigh In

Separately, Raymond James Financial initiated coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Janux Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $91.89.

Check Out Our Latest Research Report on JANX

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Janux Therapeutics by 12.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company's stock worth $5,033,000 after buying an additional 20,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Janux Therapeutics by 18.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company's stock valued at $583,000 after purchasing an additional 3,393 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Janux Therapeutics by 71.7% during the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company's stock valued at $262,000 after purchasing an additional 4,059 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Read More

Earnings History for Janux Therapeutics (NASDAQ:JANX)

Should You Invest $1,000 in Janux Therapeutics Right Now?

Before you consider Janux Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.

While Janux Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines